Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare Biotechnology

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc

Bullboard Posts

Comment by Stylesson Mar 12, 2015 10:38am

94 Views

Post# 23513356

RE:Feb 04 2015 you said yes you sold below $8

one could argue you lost the upside from 19.40 to now down to 13.45.lol

That's bad news my friend.

It's never better to have one drug vs. two or more. Ever.

It's called diversification. i guess where you went to school, they never taught you about diversification.

CPH is the only healthcare stock on my screening list that's down year to date. Sizeably down as well. Over 20%

Bullboard Posts

Quantum eMotion claps back at partner's criticism